Today, Eko Health announced FDA clearance for its Low EF (ejection fraction) detection AI platform, integrated into its digital stethoscope. With this technology, healthcare providers can identify Low EF, a key indicator of heart failure, in just 15 seconds during routine physical exams using an Eko stethoscope.
Developed in collaboration with the Mayo Clinic, this innovation aims to prevent hospitalizations and adverse events, particularly benefiting underserved areas due to the stethoscope's portability. Eko plans to incorporate the Low EF AI into its Sensora platform, enhancing cardiac disease detection alongside existing FDA-cleared algorithms for identifying AFib and structural heart murmurs. Connor Landgraf, co-founder & CEO of Eko Health, emphasised the transformative potential of this technology in improving access to care for millions of patients worldwide.
Click here to read the original news story.